Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort added to tiotropium in severe COPD
2006-006796-21Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of budesonide, formoterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Predose forced expiratory volume in 1 second. Started Mar 2007; status: completed.
02
Drugs
budesonideformoteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-006796-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006796-21.